NAD+ is a molecule your cells use to turn food into energy and to run repair systems. It cycles between two forms (NAD+ and NADH) to shuttle electrons through metabolism. It is popular in wellness clinics, but direct NAD+ shots and IVs are not proven anti-aging treatments and are not FDA-approved for general wellness claims.
NAD+ is a central redox cofactor and substrate for sirtuins, PARPs, and CD38. The strongest clinical evidence supports NAD+ precursor strategies (NR, NMN) raising NAD-related metabolites, while direct NAD+ injection remains a lower-evidence, compounding-sensitive area. Note: this is a nucleotide coenzyme, not a peptide - it is catalogued here as peptide-adjacent so it can share the Atlas protocol and biomarker framework.
NAD+ sits at the intersection of mitochondrial redox flux, NAD-consuming stress-response enzymes, CD38/CD73 extracellular metabolism, PARP-dependent DNA repair, and sirtuin-mediated transcriptional regulation. Translational uncertainty is highest for direct extracellular NAD+ delivery, because injected NAD+ may be rapidly hydrolyzed by ectoenzymes before achieving predictable intracellular NAD-pool effects.
NAD+ is the one entry in this atlas that is not a peptide - it is a nucleotide redox coenzyme, catalogued here as peptide-adjacent so it can share the protocol and biomarker framework. Its biology is foundational and mechanistically strong, but the popular wellness framing runs ahead of the evidence: direct NAD+ injection is weakly validated, while the oral precursors NR and NMN carry the stronger human data. The page keeps mechanism, the NR/NMN precursor evidence, and the compounding-safety story clearly separated.
NAD+ does two jobs. As a redox shuttle, it cycles back and forth (NAD+ ↔ NADH) to help cells make energy without being used up. But several "consumer" enzymes also burn through NAD+ to do repair and stress-response work - which is why NAD+ levels can fall under stress and aging.
NAD+ functions both as a reversible redox intermediate (feeding mitochondrial respiration) and as a consumable substrate for sirtuins, PARPs, and CD38. The repletion hypothesis is that restoring NAD+ availability supports mitochondrial function, DNA repair, and a healthier inflammatory tone - but the route matters, because injected extracellular NAD+ is rapidly degraded.
Redox cycling reversibly transfers a hydride at the nicotinamide moiety (no net NAD+ loss). In contrast, the NAD+-consuming enzyme families - PARPs/ARTDs, CD38/CD157, and sirtuins - all hydrolyze NAD+ to nicotinamide plus an ADP-ribose product, irreversibly drawing down the pool. Extracellular delivery is constrained by CD38/CD73/eNPP ectoenzyme metabolism.
This section is educational page-modeling only, not a recommendation to use NAD+. Direct NAD+ injection for wellness, anti-aging, addiction recovery, performance, or "energy" is not FDA-approved and should be treated as experimental/unvalidated; FDA specifically warned that food-grade NAD+ is not suitable for sterile compounding without appropriate processing. The strongest human dosing evidence is for the oral precursors NR/NMN - not direct NAD+. Working unit: mg.
| Band | Direct NAD+ amount | ~mg/kg at 70 kg | Basis |
|---|---|---|---|
| Micro / tolerance | 25-50 mg | 0.36-0.71 | SC/IM practice placeholder; unvalidated |
| Low | 50-250 mg | 0.71-3.57 | Injection/infusion model; outcomes unvalidated |
| Standard | 250-500 mg | 3.57-7.14 | Common IV modeling range |
| High | 500-1000 mg | 7.14-14.29 | High wellness model; strict sterility/slow infusion |
| Literature IV anchor | ~716 mg total | ~10.2 | 3 µmol/min x 6 h (human metabolome pilot) |
These are calculator/model bands only, not validated clinical recommendations. Direct NAD+ injection has no approved dose.
| Body weight | Low (1 mg/kg) | Standard (5 mg/kg) | High (10 mg/kg) |
|---|---|---|---|
| 55 kg | 55 mg | 275 mg | 550 mg |
| 65 kg | 65 mg | 325 mg | 650 mg |
| 75 kg | 75 mg | 375 mg | 750 mg |
| 85 kg | 85 mg | 425 mg | 850 mg |
| 95 kg | 95 mg | 475 mg | 950 mg |
| 105 kg | 105 mg | 525 mg | 1050 mg |
Model bands only, not validated clinical recommendations.
| Trigger | Action | Rationale |
|---|---|---|
| Nausea, cramping, anxiety, chest tightness, severe flushing | Hold or reduce | Infusion intolerance reported with IV NAD+ |
| Chills, shaking, vomiting, severe fatigue | STOP and evaluate | FDA adverse-event warning included these in injectable NAD+ reports |
| Fever, injection-site warmth, spreading redness | HARD STOP; evaluate infection/sterility | Injectable contamination is a major concern |
| Athlete uses IV >100 mL/12 h | HARD STOP unless TUE | Anti-doping method rule |
| Active cancer / recent chemotherapy | Avoid; oncology review required | NAD+/CD73/PARP biology intersects DNA repair & therapy resistance |
| Abnormal renal/hepatic labs | Hold until reviewed | Clearance/metabolite handling uncertainty |
| Pregnancy / breastfeeding | Avoid unless physician-directed | No adequate safety base |
| Biomarker | Why considered | Validated for NAD+ decisions? |
|---|---|---|
| Whole-blood NAD+ / NAD metabolome | Direct pathway marker in NR/NMN & IV NAD+ studies | Partially - exposure marker, not outcome |
| CBC / CMP / liver enzymes | General safety screen | Not validated |
| Creatinine / eGFR | Renal safety context | Not validated |
| Homocysteine | NR-SAFE noted slight initial rise with high-dose NR; methyl-donor pool intact | Not validated for direct NAD+ |
| Fasting glucose / insulin / A1c | Metabolic context (NMN trials track this) | Not validated for direct NAD+ |
| Vitals (BP/HR) | Infusion/injection safety | Safety monitoring only |
For research reconstitution arithmetic only - not a recommendation to inject NAD+. Formula: concentration = vial mg / diluent mL; draw mL = target mg / concentration; U-100 units = draw mL x 100; doses = vial mg / target mg.
The calculator handles reconstitution arithmetic only. It is not a recommendation to inject NAD+. Direct injectable NAD+ has no FDA-approved wellness indication, and food-grade NAD+ is not suitable for sterile compounding without appropriate processing. The best-evidenced way to raise NAD is oral NR/NMN, not direct injection. Use only under appropriate medical and regulatory oversight.
The dominant injectable risk; food-grade NAD+ bulk is not suitable for sterile compounding - verify pharmaceutical-grade, low-endotoxin sourcing.
Verify research vials against supplier COA and mass spec; avoid unsourced online or food-grade bulk for any injectable use.
Injected NAD+ is rapidly degraded by ectoenzymes; do not expect injectable behavior to mirror intracellular NAD synthesis or oral precursors.
For raising NAD metabolites, oral NR/NMN carry the stronger human evidence and avoid the sterile-injectable risk entirely.
IV infusions >100 mL per 12 h are prohibited in sport without a TUE/medical exception - a method rule, independent of NAD+ itself.
NAD+/CD73/PARP biology intersects DNA repair and therapy resistance; avoid in active malignancy without oncology review.
NAD+ "stacks" are largely practice-pattern theory. Pairing NAD+ with its own precursors is more redundant than synergistic; pairing it with mitochondrial supplements or metabolic drugs borrows evidence from unrelated literatures. The engine treats malignancy as a hard constraint because the NAD+/CD73/PARP axis intersects DNA repair and therapy resistance.
Active malignancy, current chemotherapy, or a high-risk cancer context requires caution because the NAD+/CD73/PARP pathways intersect with DNA repair and therapy-resistance biology - do not stack without oncology review. More broadly, NAD+ stacks borrow evidence from adjacent literatures; the only human-validated way to raise NAD shown here is oral NR/NMN, and even that is an exposure effect, not a proven outcome. Verify sterile-injectable quality, and respect the athlete IV-volume rule.
For NAD+, the dominant safety story is not exotic pharmacology - it is injectable quality. FDA reported chills, shaking, vomiting, and fatigue after injectable NAD+ drugs, with some cases requiring treatment, consistent with excessive endotoxin exposure, and warned that food-grade NAD+ is not suitable for sterile compounding. Layered on top are infusion intolerance, the athlete IV-volume rule, and cancer-biology cautions from the DNA-repair axis. The oral precursors (NR/NMN) have been generally well tolerated in trials.
| Condition | Concern | Severity |
|---|---|---|
| Known allergy to NAD+ formulation/excipients | Hypersensitivity risk | High |
| Active infection / fever | Avoid elective injection/IV | High |
| Pregnancy / breastfeeding | Insufficient safety evidence | High |
| Active malignancy / chemotherapy | DNA-repair / CD73 / PARP biology uncertainty | High |
| Athlete subject to WADA rules | IV-volume violation risk (>100 mL/12 h) | High |
| Unverified online vial / food-grade bulk | Sterility / endotoxin risk | High |
| Severe renal disease | Unclear metabolite handling | Moderate-High |
| Severe hepatic disease | Unclear metabolism / safety | Moderate-High |
| Mast-cell instability / infusion reactions | Higher reaction risk | Moderate-High |
| Concurrent high-dose NR/NMN/niacinamide | Redundant methylation / metabolite load | Moderate |
BP, HR, and symptoms before/during/after; stop for chills, shaking, vomiting, or severe flushing.
The single most important step for any injectable use; verify pharmaceutical-grade, low-endotoxin product.
Whole-blood NAD+ tracks exposure (used in NR/NMN and IV NAD+ studies) but is not an outcome marker.
Baseline and review for complex or high-dose patients; hold on abnormalities.
Active or recent malignancy is a hard caution; oncology review before any NAD-axis loading.
For raising NAD with the strongest evidence and least injectable risk, oral NR/NMN is the better-supported path.
NAD+ biology is foundational and mechanistically strong, but direct NAD+ injection protocols are clinically underdeveloped. The human evidence is strongest for the precursors NR and NMN raising NAD-related metabolites; direct IV NAD+ has only pilot metabolome/tolerability data, and large randomized outcome trials for anti-aging, wellness, addiction recovery, fatigue, or performance are lacking.
A pilot study of a 6-hour IV NAD+ infusion (3 µmol/min, ~716 mg total) measured changes in the human plasma and urine NAD+ metabolome - establishing measurable exposure, but not clinical efficacy.
A comparative human study of IV NAD+ versus IV NR reported that IV NAD+ produced more moderate/severe symptoms and longer infusion times - a tolerability-relevant contrast favoring the precursor on the IV route.
A randomized placebo-controlled trial of oral NR in older adults with MCI increased blood NAD+ and was well tolerated, but did not change cognition - a clean example of raising NAD without a demonstrated functional outcome.
A randomized double-blind phase I trial of NR 1500 mg twice daily for 4 weeks was well tolerated and raised blood NAD+ up to ~5-fold, supporting further trials.
NMN up to 900 mg/day raised blood NAD and was well tolerated, and NMN 250 mg/day for 12 weeks in older men raised NAD+ metabolites and altered muscle function, with functional signals needing validation.
NAD+ is consumed by sirtuins, PARPs, and CD38 and is central to aging/disease biology; CD38 is required for age-related NAD decline and mitochondrial dysfunction via an SIRT3-dependent mechanism, and intranasal NAD+ reduced brain injury in a rat ischemia model.
NAD+ biology is foundational and mechanistically strong (redox metabolism plus sirtuin/PARP/CD38 consumption), but direct NAD+ injection is clinically underdeveloped. Human evidence is strongest for precursors (NR/NMN) raising NAD-related metabolites (e.g. ~5-fold with high-dose NR) - though even there, raising NAD is an exposure effect that has not consistently translated into functional outcomes (no cognition change in the NR MCI trial). Direct IV NAD+ has only pilot metabolome/tolerability data. NAD+ belongs on the Atlas as a foundational metabolic cofactor and a legitimate repletion target - best approached through precursors - and explicitly not as a proven anti-aging or performance injectable.
| Study / source | Setting | Result | Grade |
|---|---|---|---|
| Grant 2019 | IV NAD+ pilot (~716 mg / 6 h) | Plasma/urine NAD metabolome changed; not efficacy | B/D |
| Reyna 2026 | IV NAD+ vs IV NR | NAD+ IV: more moderate/severe symptoms, longer infusion | B/D |
| Orr 2024 | NR RCT in MCI | Raised NAD+, well tolerated, no cognition change | A/B |
| NR-SAFE 2023 | High-dose NR phase I (Parkinson's) | Well tolerated; NAD+ up to ~5-fold | B |
| Yi 2023 | NMN RCT (up to 900 mg/d) | Raised NAD, well tolerated | B |
| Igarashi 2022 | NMN 250 mg/d x 12 wk, older men | Raised NAD metabolites; muscle-function signals | B |
| Kane & Sinclair 2018 | Mechanistic review | NAD consumed by sirtuins/PARPs/CD38 | P |
| Camacho-Pereira 2016 | CD38 aging model | CD38 drives age-related NAD decline (SIRT3) | C/P |
| Ying 2007 | Rat focal ischemia | Intranasal NAD+ reduced infarct/deficits | C |
The most useful comparison is NAD+ versus the molecules used to raise it. Direct NAD+ is the coenzyme itself but is hard to deliver intact; NR and NMN are precursors with the stronger human data; and niacin/nicotinamide are the classical vitamin-B3 forms with established pharmacology but different profiles (flushing, lipid effects, methylation load).
| Feature | NAD+ (direct) | Nicotinamide riboside (NR) | Nicotinamide mononucleotide (NMN) | Niacin / nicotinamide |
|---|---|---|---|---|
| Role | The coenzyme itself | NAD+ precursor | NAD+ precursor | Vitamin B3 precursor |
| Pathway | Direct repletion | NRK → NMN → NAD | NMNAT → NAD | Preiss-Handler / salvage |
| Evidence tier | Direct IV B/D; mechanism P/C | Human RCTs / phase I | Human RCTs (small-moderate) | Established vitamin pharmacology |
| Route | IV, SC, IM, intranasal, oral discussed | Oral (IV emerging) | Oral | Oral |
| Delivery issue | Rapid ectoenzyme degradation | Efficient NAD raise | Efficient NAD raise | Flushing (niacin); methylation load |
| Regulatory status | Not FDA-approved injection; compounding warning | Dietary ingredient / investigational | Supplement/drug context varies | Approved vitamin forms |
| Key caution | Sterility/endotoxin; unproven outcomes | Mild homocysteine rise (high dose) | Regulatory status varies by market | Niacin flush; high-dose hepatic caution |